Cargando…
Efficacy and safety of lanthanum carbonate on chronic kidney disease–mineral and bone disorder in dialysis patients: a systematic review
BACKGROUND: Chronic kidney disease–mineral and bone disorder (CKD–MBD) is a common complication in CKD patients, particularly in those with end-stage renal disease that requires dialysis. Lanthanum carbonate (LC) is a potent, non-aluminum, non-calcium phosphate binder. This systematic review evaluat...
Autores principales: | Zhang, Chenglong, Wen, Ji, Li, Zi, Fan, Junming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853136/ https://www.ncbi.nlm.nih.gov/pubmed/24134531 http://dx.doi.org/10.1186/1471-2369-14-226 |
Ejemplares similares
-
Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
por: Gros, Blanca, et al.
Publicado: (2015) -
An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis
por: Wasilewska, Anna, et al.
Publicado: (2022) -
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019) -
Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure
por: Damment, Stephen, et al.
Publicado: (2011) -
Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate
por: Mohammed, Ismail A, et al.
Publicado: (2008)